Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for February 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Cancer Risk Up in Bilateral Retinoblastoma Survivors
THURSDAY, Feb. 23 (HealthDay News) -- For survivors of bilateral retinoblastoma (Rb), family history is associated with an increased risk of second cancers (SCs), especially melanoma, according to a study published online Feb. 21 in the Journal of Clinical Oncology.
Alcohol Dependence Significant Problem for U.S. Surgeons
TUESDAY, Feb. 21 (HealthDay News) -- A considerable number of U.S. surgeons have alcohol abuse and dependence, which is more likely in those who have recently reported major errors, are burned out, and are depressed, according to a study published in the February issue of the Archives of Surgery.
Cell Abnormality Linked to Diabetic Retinopathy
FRIDAY, Feb. 17 (HealthDay News) -- Type 1 diabetes patients with early retinopathy have abnormalities in their endothelial progenitor cells (EPC), a cell type released into the circulation as a result of vascular damage, according to a study published online Feb. 14 in Diabetes.
Open-Angle Glaucoma Linked to Erectile Dysfunction
FRIDAY, Feb. 17 (HealthDay News) -- Men with erectile dysfunction (ED) are almost three times more likely to have been previously diagnosed with glaucoma, according to a study published in the February issue of Ophthalmology.
High Omega-3 Intake Slows Rate of Visual Acuity Decline
THURSDAY, Feb. 16 (HealthDay News) -- For patients with typical retinitis pigmentosa, treatment with vitamin A combined with an omega-3-rich diet slows the decline in distance and retinal visual acuities, according to a study published online Feb. 13 in the Archives of Ophthalmology.
New Method Found to Detect Sensorimotor Polyneuropathy
WEDNESDAY, Feb. 15 (HealthDay News) -- Corneal nerve fiber length (CNFL), as measured using corneal confocal microscopy (CCM), can be used to reliably rule diabetic sensorimotor polyneuropathy (DSP) in or out, according to research published online Feb. 8 in Diabetes Care.
Procedure, Medication Both Cost-Effective in Glaucoma
TUESDAY, Feb. 14 (HealthDay News) -- Generic topical prostaglandin analogs (PGAs) and treatment with laser trabeculoplasty (LTP) are both cost-effective for treatment of newly diagnosed mild open-angle glaucoma, with PGAs providing better quality of life relative to LTP, according to a study published online Feb. 13 in the Archives of Ophthalmology.
Zioptan Eyedrops Approved for Glaucoma, Ocular Hypertension
MONDAY, Feb. 13 (HealthDay News) -- Merck's Zioptan drops (tafluprost ophthalmic solution) have been approved by the U.S. Food and Drug Administration to lower pressure within the eye among people with high blood pressure of the eye (ocular hypertension) or open-angle glaucoma, the most common form of the disease.
Gene Therapy for Blindness Safe in Second Eye
WEDNESDAY, Feb. 8 (HealthDay News) -- For patients with a hereditary form of blindness previously treated with gene therapy in one eye, a second dose of gene therapy in the other eye is safe and improves vision even further, according to a study published in the Feb. 8 issue of Science Translational Medicine.
Copyright © 2012 ScoutNews, LLC. All rights reserved.
|Previous: February 2012 Briefing - Hematology & Oncology||Next: February 2012 Briefing - Orthopedics|
Reader comments on this article are listed below. Review our comments policy.
Submit your opinion:
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community